Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Price:
82.44 USD
-1.62%
Market Closed
Updated:
May 4, 2024
Biomarin Pharmaceutical Inc
Net Income (Common)
|
Biomarin Pharmaceutical Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
Net Income (Common)
$205.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Biomarin Pharmaceutical Inc's Net Income (Common)?
Net Income (Common)
205.4m
USD
205.4m
USD
Based on the financial report for Mar 31, 2024, Biomarin Pharmaceutical Inc's Net Income (Common) amounts to 205.4m USD.
What is Biomarin Pharmaceutical Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-36%
-36%
Over the last year, the Net Income (Common) growth was 187%. The average annual Net Income (Common) growth rates for Biomarin Pharmaceutical Inc have been -36% over the past three years .
You don't have any saved screeners yet
